Cardiorenal syndrome type 4: A review

CardioRenal Medicine

Volumn 3, Issue 1, 2013, Pages 63-70

  Clementi, Anna ^a,b   Virzì, Grazia Maria ^b,c   Goh, Ching Yan ^b,d   Cruz, Dinna N ^b,c   Granata, Antonio ^a   Vescovo, Girogio ^c   Ronco, Claudio ^b,c  

^a SAN GIOVANNI DI DIO HOSPITAL   (Italy)

^b International Renal Research Institute (IRRI)   (Italy)

^c SAN BORTOLO HOSPITAL   (Italy)

^d Batu Caves   (Malaysia)

Author keywords

Biomarkers; Cardiorenal syndrome type 4; Cardiovascular events; Chronic kidney disease

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; HOMOCYSTEINE; ISCHEMIA MODIFIED ALBUMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERUM AMYLOID A; TROPONIN T;

CARDIORENAL SYNDROME; CARDIORENAL SYNDROME TYPE 4; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DIASTOLIC DYSFUNCTION; HEART FUNCTION; HEART VENTRICLE HYPERTROPHY; HUMAN; INCIDENCE; MORBIDITY; MORTALITY; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYMPATHETIC TONE;

EID: 84897489168     PISSN: 16643828     EISSN: 16645502     Source Type: Journal    
DOI: 10.1159/000350397     Document Type: Review

References (67)

1. Ronco C, Chionh CY, Haapio M, Anavekar NS, House A, Bellomo R: The cardiorenal syndrome. Blood Purif 2009; 27: 114-126.
2. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R: Cardiorenal syndrome. J Am Coll Cardiol 2008; 52: 1527-1539.
3. Ronco C, House AA, Haapio M: Cardiorenal syndrome: refining the definition of a complex symbiosis gone wrong. Intensive Care Med 2008; 34: 957-962.
4. Ronco C, House AA, Haapio M: Cardiorenal and renocardiac syndromes: the need for a comprehensive classification and consensus. Nat Clin Pract Nephrol 2008; 4: 310-311.
5. Garg AX, Clark WF, Haynes RB, House AA: Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I. Kidney Int 2002; 61: 1486-1494.
6. Sarnak MJ, Coronado BE, Greene T, Wang SR, Kusek JW, Beck GJ, Levey AS: Cardiovascular disease risk factors in chronic renal insufficiency. Clin Nephrol 2002; 57: 327-335.
7. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
8. Stenvinkel P, Barany P, Heimburger O, Pecoits-Filho R, Lindholm B: Mortality, malnutrition, and atherosclerosis in ESRD: what is the role of interleukin-6? Kidney Int Suppl 2002; 80: 103-108.
9. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW: Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154-2169.
10. Ruggenenti P, Schieppati A, Remuzzi G: Progression, remission, regression of chronic renal diseases. Lancet 2001; 357: 1601-1608.
11. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S: Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134: 629-636.
12. Hallan SI, Stevens P: Screening for chronic kidney disease: which strategy? J Nephrol 2010; 23: 147-155.
13. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G: National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137-147.
14. Muntner P, Anderson A, Charleston J, Chen Z, Ford V, Makos G, O'Connor A, Perumal K, Rahman M, Steigerwalt S, Teal V, Townsend R, Weir M, Wright JT Jr: Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis 2010; 55: 441-451.
15. Thomas R, Kanso A, Sedor JR: Chronic kidney disease and its complications. Prim Care 2008; 35: 329-344.
16. Hutchison JA: Vascular calcification in dialysis patients. Prilozi 2007; 28: 215-224.
17. Kramer H, Toto R, Peshock R, Cooper R, Victor R: Association between chronic kidney disease and coronary artery calcification: the DALLAS Heart Study. J Am Soc Nephrol 2005; 16: 507-513.
18. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C: Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55: 648-658.
19. Noh H, Lee SW, Kang SW, Shin SK, Choi KH, Lee HY, Han DS: Serum C-reactive protein: a predictor of mortality in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1998; 18: 387-394.
20. Schiffrin EL, Lipman ML, Mann JF: Chronic kidney disease: effects on the cardiovascular system. Circulation 2007; 116: 85-97.
21. Meyer TW, Hostetter TH: Uremia. N Engl J Med 2007; 357: 1316-1325.
22. Middleton JP, Pun PH: Hypertension, chronic kidney disease, and the development of cardiovascular risk: a joint primacy. Kidney Int 2010; 77: 753-755.
23. Navab KD, Elboudwarej O, Gharif M, Yu J, Hama SY, Safarpour S, Hough GP, Vakili L, Reddy ST, Navab M, Vaziri ND: Chronic inflammatory disorders and accelerated atherosclerosis: Chronic kidney disease. Curr Pharm Des 2011; 17: 17-20.
24. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-1483.
25. Hakim RM: Clinical implications of hemodialysis membrane biocompatibility. Kidney Int 1993; 44: 484-494.
26. Amore A, Bonaudo R, Ghigo D, Arese M, Costamagna C, Cirina P, Gianoglio B, Perugini L, Coppo R: Enhanced production of nitric oxide by blood-dialysis membrane interaction. J Am Soc Nephrol 1995; 6: 1278-1283.
27. Tielemans C, Husson C, Schurmans T, Gastaldello K, Madhoun P, Delville JP, Marchant A, Goldman M, Vanherweghem JL: Effects of ultrapure and non-sterile dialysate on the inflammatory response during in vitro hemodialysis. Kidney Int 1996; 49: 236-243.
28. Ashby DR, Power A, Singh S, Choi P, Taube DH, Duncan ND, Cairns TD: Bacteremia associated with tunneled hemodialysis catheters: outcome after attempted salvage. Clin J Am Soc Nephrol 2009; 4: 1601-1605.
29. Goldstein SL, Ikizler TA, Zappitelli M, Silverstein DM, Ayus JC: Non-infected hemodialysis catheters are associated with increased inflammation compared to arteriovenous fistulas. Kidney Int 2009; 76: 1063-1069.
30. Agarwal R, Weir MR: Dry-weight: a concept revisited in an effort to avoid medication-directed approaches for blood pressure control in hemodialysis patients. Clin J Am Soc Nephrol 2010; 5: 1255-1260.
31. Stegmayr BG: Ultrafiltration and dry weight-what are the cardiovascular effects? Artif Organs 2003; 27: 227-229.
32. Chung SH, Heimburger O, Stenvinkel P, Wang T, Lindholm B: Influence of peritoneal transport rate, inflammation, and fluid removal on nutritional status and clinical outcome in prevalent peritoneal dialysis patients. Perit Dial Int 2003; 23: 174-183.
33. Fassett RG, Driver R, Healy H, Coombes JS: Cardiovascular disease in peritoneal dialysis patients. Panminerva Med 2009; 51: 151-161.
34. Mutluay R, Konca C, Erten Y, Pasaoglu H, Deger SM, Agirgun C, Derici U, Arinsoy T, Sindel S: Predictive markers of asymptomatic atherosclerosis in end-stage renal disease patients. Ren Fail 2010; 32: 448-454.
35. Arikan H, Koc M, Tuglular S, Ozener C, Akoglu E: Elevated plasma levels of PAI-1 predict cardiovascular events and cardiovascular mortality in prevalent peritoneal dialysis patients. Ren Fail 2009; 31: 438-445.
36. Daniels LB, Maisel AS: Natriuretic peptides. J Am Coll Cardiol 2007; 50: 2357-2368.
37. DeFilippi CR, Fink JC, Nass CM, Chen H, Christenson R: N-terminal pro-B-type natriuretic peptide for predicting coronary disease and left ventricular hypertrophy in asymptomatic CKD not requiring dialysis. Am J Kidney Dis 2005; 46: 35-44.
38. Codognotto M, Piccoli A, Zaninotto M, Mion MM, Ruzza L, Barchita A, Naso A, Plebani M: Effect of a dialysis session on the prognostic values of NT-proBNP, troponins, endothelial damage and inflammation biomarkers. J Nephrol 2010; 23: 465-471.
39. Wang AY, Lam CW, Yu CM, Wang M, Chan IH, Zhang Y, Lui SF, Sanderson JE: N-terminal pro-brain natriuretic peptide: an independent risk predictor of cardiovascular congestion, mortality, and adverse cardiovascular outcomes in chronic peritoneal dialysis patients. J Am Soc Nephrol 2007; 18: 321-330.
40. Ooi DS, Zimmerman D, Graham J, Wells GA: Cardiac troponin T predicts long-term outcomes in hemodialysis patients. Clin Chem 2001; 47: 412-417.
41. Dierkes J, Domrose U, Westphal S, Ambrosch A, Bosselmann HP, Neumann KH, Luley C: Cardiac troponin T predicts mortality in patients with end-stage renal disease. Circulation 2000; 102: 1964-1969.
42. Mallamaci F, Zoccali C, Parlongo S, Tripepi G, Benedetto FA, Cutrupi S, Bonanno G, Fatuzzo P, Rapisarda F, Seminara G, Stancanelli B, Bellanuova I, Cataliotti A, Malatino LS: Troponin is related to left ventricular mass and predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2002; 40: 68-75.
43. Iwanaga Y, Miyazaki S: Heart failure, chronic kidney disease, and biomarkers-an integrated viewpoint. Circ J 2010; 74: 1274-1282.
44. Ix JH, Shlipak MG, Chertow GM, Whooley MA: Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study. Circulation 2007; 115: 173-179.
45. Patel PC, Ayers CR, Murphy SA, Peshock R, Khera A, de Lemos JA, Balko JA, Gupta S, Mammen PP, Drazner MH, Markham DW: Association of cystatin C with left ventricular structure and function: the DALLAS Heart Study. Circ Heart Fail 2009; 2: 98-104.
46. Hemdahl AL, Gabrielsen A, Zhu C, Eriksson P, Hedin U, Kastrup J, Thoren P, Hansson GK: Expression of neutrophil gelatinase-associated lipocalin in atherosclerosis and myocardial infarction. Arterioscler Thromb Vasc Biol 2006; 26: 136-142.
47. Yndestad A, Landro L, Ueland T, Dahl CP, Flo TH, Vinge LE, Espevik T, Froland SS, Husberg C, Christensen G, Dickstein K, Kjekshus J, Oie E, Gullestad L, Aukrust P: Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure. Eur Heart J 2009; 30: 1229-1236.
48. Zografos T, Haliassos A, Korovesis S, Giazitzoglou E, Voridis E, Katritsis D: Association of neutrophil gelatinaseassociated lipocalin with the severity of coronary artery disease. Am J Cardiol 2009; 104: 917-920.
49. Koomans HA, Blankestijn PJ, Joles JA: Sympathetic hyperactivity in chronic renal failure: a wake-up call. J Am Soc Nephrol 2004; 15: 524-537.
50. Schmieder RE, Delles C, Mimran A, Fauvel JP, Ruilope LM: Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care 2007; 30: 1351-1356.
51. Pun PH, Lehrich RW, Smith SR, Middleton JP: Predictors of survival after cardiac arrest in outpatient hemodialysis clinics. Clin J Am Soc Nephrol 2007; 2: 491-500.
52. Dohi Y, Ohashi M, Sugiyama M, Takase H, Sato K, Ueda R: Candesartan reduces oxidative stress and inflammation in patients with essential hypertension. Hypertens Res 2003; 26: 691-697.
53. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
54. Takahashi A, Takase H, Toriyama T, Sugiura T, Kurita Y, Ueda R, Dohi Y: Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis-a randomized study. Nephrol Dial Transplant 2006; 21: 2507-2512.
55. Suzuki H, Kanno Y, Sugahara S, Ikeda N, Shoda J, Takenaka T, Inoue T, Araki R: Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. Am J Kidney Dis 2008; 52: 501-506.
56. Chonchol M, Benderly M, Goldbourt U: Beta-blockers for coronary heart disease in chronic kidney disease. Nephrol Dial Transplant 2008; 23: 2274-2279.
57. Cice G, Ferrara L, D'Andrea A, D'Isa S, Di Benedetto A, Cittadini A, Russo PE, Golino P, Calabro R: Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebocontrolled trial. J Am Coll Cardiol 2003; 41: 1438-1444.
58. Koch M, Thomas B, Tschope W, Ritz E: Survival and predictors of death in dialysed diabetic patients. Diabetologia 1993; 36: 1113-1117.
59. Ritz E, Dikow R, Adamzcak M, Zeier M: Congestive heart failure due to systolic dysfunction: The Cinderella of cardiovascular management in dialysis patients. Semin Dial 2002; 15: 135-140.
60. Borazan A, Ustun H, Ustundag Y, Aydemir S, Bayraktaroglu T, Sert M, Yilmaz A: The effects of peritoneal dialysis and hemodialysis on serum tumor necrosis factor-alpha, interleukin-6, interleukin-10 and C-reactiveprotein levels. Mediators Inflamm 2004; 13: 201-204.
61. Pupim LB, Himmelfarb J, McMonagle E, Shyr Y, Ikizler TA: Influence of initiation of maintenance hemodialysis on biomarkers of inflammation and oxidative stress. Kidney Int 2004; 65: 2371-2379.
62. Macleod AM, Campbell M, Cody JD, Daly C, Donaldson C, Grant A, Khan I, Rabindranath KS, Vale L, Wallace S: Cellulose, modified cellulose and synthetic membranes in the haemodialysis of patients with end-stage renal disease. Cochrane Database Syst Rev 2005:CD003234.
63. House AA, Wells GA, Donnelly JG, Nadler SP, Hebert PC: Randomized trial of high-flux vs low-flux haemodialysis: effects on homocysteine and lipids. Nephrol Dial Transplant 2000; 15: 1029-1034.
64. Chauveau P, Nguyen H, Combe C, Chene G, Azar R, Cano N, Canaud B, Fouque D, Laville M, Leverve X, Roth H, Aparicio M: Dialyzer membrane permeability and survival in hemodialysis patients. Am J Kidney Dis 2005; 45: 565-571.
65. Gerdemann A, Wagner Z, Solf A, Bahner U, Heidland A, Vienken J, Schinzel R: Plasma levels of advanced glycation end products during haemodialysis, haemodiafiltration and haemofiltration: potential importance of dialysate quality. Nephrol Dial Transplant 2002; 17: 1045-1049.
66. Lin CL, Yang CW, Chiang CC, Chang CT, Huang CC: Long-term on-line hemodiafiltration reduces predialysis beta-2-microglobulin levels in chronic hemodialysis patients. Blood Purif 2001; 19: 301-307.
67. Canaud B, Morena M, Leray-Moragues H, Chalabi L, Cristol JP: Overview of clinical studies in hemodiafiltration: what do we need now? Hemodial Int 2006; 10(suppl 1):S5-S12.